Molidustat clinical trials
Also written BAY85-3934.
How each study uses molidustat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2014 (4)
| Year | Studies |
|---|---|
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 0
Studies
Open first, then newest update. How each study uses molidustat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- A Study of Molidustat for Correction of Renal Anemia in Dialysis SubjectsCompletedPhase 3BayerNCT03351166Written as Molidustat (BAY85-3934)How we know
- A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis SubjectsCompletedPhase 3BayerNCT03418168Written as Molidustat (BAY85-3934)How we know
- Maintenance Treatment of Renal Anemia in Dialysis SubjectsCompletedPhase 3BayerNCT03543657Written as Molidustat (BAY85-3934)How we know
- A Study of Molidustat for Correction of Renal Anemia in Non-dialysis SubjectsCompletedPhase 3BayerNCT03350321Written as Molidustat (BAY85-3934)How we know
- A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis SubjectsCompletedPhase 3BayerNCT03350347Written as Molidustat (BAY85-3934)How we know
- Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched SubjectsCompletedPhase 1BayerNCT01318551Written as BAY85-3934How we know
- To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy SubjectsCompletedPhase 1BayerNCT02312973Written as Molidustat(BAY85-3934)How we know
- Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934CompletedPhase 2BayerNCT02064426Written as Molidustat (BAY85-3934)How we know
- Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934CompletedPhase 2BayerNCT01975818Written as Molidustat (BAY 85-3934)How we know
- 15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)CompletedPhase 2BayerNCT02021370Written as BAY85-3934How we know
- Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934CompletedPhase 2BayerNCT02021409Written as BAY85-3934How we know
- Long-term Pre-dialysis Extension in Europe and Asia PacificCompletedPhase 2BayerNCT02055482Written as Molidustat (BAY85-3934)How we know
- Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)CompletedPhase 1BayerNCT01679587Written as Molidustat (BAY85-3934)How we know
- Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)CompletedPhase 1BayerNCT01332942Written as BAY85-3934How we know
- Age and Gender Effects on the Pharmacokinetics of BAY85-3934CompletedPhase 1BayerNCT01458028Written as BAY85-3934How we know
Codes
What other systems call molidustat · ClinicalTrials.gg INT000369
- MeSH (NLM) C000603972molidustatOne source NLM
- UNII (FDA) 9JH486CZ13MOLIDUSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27087553molidustatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174580MolidustatOne source FDA
- DrugBank DB15642One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000603972 | molidustat | One source NLM |
| UNII (FDA) | 9JH486CZ13 | MOLIDUSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27087553 | molidustat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174580 | Molidustat | One source FDA |
| DrugBank | DB15642 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.